NZ741406A - Neuroactive steroid formulations and methods of treating cns disorders - Google Patents
Neuroactive steroid formulations and methods of treating cns disordersInfo
- Publication number
- NZ741406A NZ741406A NZ74140613A NZ74140613A NZ741406A NZ 741406 A NZ741406 A NZ 741406A NZ 74140613 A NZ74140613 A NZ 74140613A NZ 74140613 A NZ74140613 A NZ 74140613A NZ 741406 A NZ741406 A NZ 741406A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- cns disorders
- neuroactive steroid
- treating cns
- steroid formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 abstract 1
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000007979 citrate buffer Substances 0.000 abstract 1
- 239000011521 glass Substances 0.000 abstract 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed is an aqueous pharmaceutical composition comprising allopregnanolone at a concentration of about 5 mg/mL, sulfo butyl ether β-cyclodextrin at a concentration of about 250 mg/mL, and a citrate buffer, wherein the pH of the composition is from 5 to 9, and wherein the aqueous pharmaceutical composition is contained within a glass vial.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ755699A NZ755699B2 (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating CNS disorders |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261589740P | 2012-01-23 | 2012-01-23 | |
| NZ72434513 | 2013-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ741406A true NZ741406A (en) | 2019-11-29 |
Family
ID=68652880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ74140613A NZ741406A (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating cns disorders |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ741406A (en) |
-
2013
- 2013-01-23 NZ NZ74140613A patent/NZ741406A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ597354A (en) | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | |
| AU2013334740A8 (en) | Stable, low viscosity antibody formulation | |
| PH12017502355A1 (en) | Neuroactive steroid solutions and their methods of use | |
| MX2022010976A (en) | Neuroactive steroid formulations and methods of treating cns disorders. | |
| JP2015513316A5 (en) | ||
| MX361218B (en) | Spliceostatin analogs. | |
| SG171542A1 (en) | Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin | |
| MX351148B (en) | Abeta antibody formulation. | |
| PH12012502159A1 (en) | Pharmaceutical compositions and methods of making same | |
| PH12016500814A1 (en) | Heteroaryl butanoic acid derivatives | |
| NZ719185A (en) | Crystalline forms of therapeutic compounds and uses thereof | |
| MX2015010829A (en) | Therapeutic compounds and uses thereof. | |
| AR098168A1 (en) | STABLE FORMULATION OF GLULISINE INSULIN | |
| PH12014500240A1 (en) | Formulations of deoxycholic acid and salts thereof | |
| PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| PH12015502720A1 (en) | Complex granule formulation having improved stability comprising levocetirizine and montelukast | |
| PH12015502717B1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| MX2017015202A (en) | Liquid formulations of celecoxib for oral administration. | |
| NZ741406A (en) | Neuroactive steroid formulations and methods of treating cns disorders | |
| MX2016002930A (en) | Liver x receptor (lxr) modulators. | |
| GEP201706769B (en) | Composition of tiacumicin compounds | |
| WO2009043577A3 (en) | Contraceptive 19-nor progesterones | |
| IN2014DN07897A (en) | ||
| 원종욱 | National Pension Fund’s Welfare Investment through Purchasing Public Bonds of Welfare Purpose | |
| UA84626U (en) | Method for producing of water-soluble composition of nanoparticles containing selenium nanoparticles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 23 JAN 2023 BY COMPUTER PACKAGES INC Effective date: 20200501 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2024 BY CPA GLOBAL Effective date: 20221209 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2025 BY CPA GLOBAL Effective date: 20231207 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241227 |